Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
210 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H2 2016, provides an overview of the Gastrointestinal Stromal Tumor (Oncology) pipeline landscape. Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastrointestinal Stromal Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Gastrointestinal Stromal Tumor. Gastrointestinal Stromal Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (Oncology). - The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastrointestinal Stromal Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Gastrointestinal Stromal Tumor (GIST) Overview 10 Therapeutics Development 11 Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 11 Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 12 Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 13 Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 15 Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19 Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 21 Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 22 AB Science SA 22 Advanced Accelerator Applications S.A. 23 Advenchen Laboratories, LLC 24 Ariad Pharmaceuticals, Inc. 25 Arog Pharmaceuticals, Inc. 26 ArQule, Inc. 27 Array BioPharma Inc. 28 Astex Pharmaceuticals Inc 29 Blueprint Medicines Corporation 30 Boston Biomedical, Inc. 31 Calithera Biosciences, Inc. 32 Chipscreen Biosciences Ltd 33 Daiichi Sankyo Company, Limited 34 Deciphera Pharmaceuticals, LLC 35 F. Hoffmann-La Roche Ltd. 36 Horizon Pharma Plc 37 Immunicum AB 38 Jiangsu Hengrui Medicine Co., Ltd. 39 Kolltan Pharmaceuticals, Inc. 40 Natco Pharma Limited 41 Nerviano Medical Sciences S.r.l. 42 Novartis AG 43 Omeros Corporation 44 Plexxikon Inc. 45 Rhizen Pharmaceuticals S.A. 46 Taiho Pharmaceutical Co., Ltd. 47 Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Combination Products 49 Assessment by Target 50 Assessment by Mechanism of Action 53 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 alpelisib - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 amcasertib - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 apatinib - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 ARQ-092 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 binimetinib - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 BLU-285 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 buparlisib hydrochloride - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 CB-839 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 CHMFLKIT-110 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 crenolanib besylate - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 CS-2164 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 DCC-2618 - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 everolimus - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 infigratinib - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 interferon gamma-1b - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 Intuvax - Drug Profile 123 Product Description 123 Mechanism Of Action 123 R&D Progress 123 KTN-0158 - Drug Profile 129 Product Description 129 Mechanism Of Action 129 R&D Progress 129 masitinib - Drug Profile 131 Product Description 131 Mechanism Of Action 131 R&D Progress 131 nilotinib - Drug Profile 144 Product Description 144 Mechanism Of Action 144 R&D Progress 144 NMSP-088 - Drug Profile 149 Product Description 149 Mechanism Of Action 149 R&D Progress 149 NRCAN-019 - Drug Profile 150 Product Description 150 Mechanism Of Action 150 R&D Progress 150 onalespib - Drug Profile 152 Product Description 152 Mechanism Of Action 152 R&D Progress 152 Peptide to Antagonize GRPR for Oncology - Drug Profile 156 Product Description 156 Mechanism Of Action 156 R&D Progress 156 pexidartinib - Drug Profile 157 Product Description 157 Mechanism Of Action 157 R&D Progress 157 PLX-9486 - Drug Profile 161 Product Description 161 Mechanism Of Action 161 R&D Progress 161 ponatinib hydrochloride - Drug Profile 162 Product Description 162 Mechanism Of Action 162 R&D Progress 162 SF-1126 - Drug Profile 175 Product Description 175 Mechanism Of Action 175 R&D Progress 175 SHR-1020 - Drug Profile 177 Product Description 177 Mechanism Of Action 177 R&D Progress 177 Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 179 Product Description 179 Mechanism Of Action 179 R&D Progress 179 Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 180 Product Description 180 Mechanism Of Action 180 R&D Progress 180 TAS-116 - Drug Profile 181 Product Description 181 Mechanism Of Action 181 R&D Progress 181 TGR-1202 - Drug Profile 182 Product Description 182 Mechanism Of Action 182 R&D Progress 182 vemurafenib - Drug Profile 189 Product Description 189 Mechanism Of Action 189 R&D Progress 189 Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 196 Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 197 Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 198 Featured News & Press Releases 198 Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 198 Jul 13, 2016: Boston Biomedical Announces Generic Name of BBI-503: Amcasertib 198 May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting 199 Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting 200 Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 201 Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 201 Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 202 Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 202 Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 203 Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 204 Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 205 Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 206 Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 206 Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor 207 Feb 01, 2012: AB Science Reports Encouraging Results From Phase II Study With Its Investigational Drug, Masitinib 207 Appendix 209 Methodology 209 Coverage 209 Secondary Research 209 Primary Research 209 Expert Panel Validation 209 Contact Us 209 Disclaimer 210
List of Tables Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016 11 Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Development by Companies, H2 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2016 22 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications S.A., H2 2016 23 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H2 2016 24 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 25 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016 26 Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule, Inc., H2 2016 27 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H2 2016 28 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 29 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H2 2016 30 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H2 2016 31 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H2 2016 32 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 33 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 35 Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2016 37 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2016 38 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 40 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H2 2016 41 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 42 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2016 43 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H2 2016 44 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H2 2016 45 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 46 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 47 Assessment by Monotherapy Products, H2 2016 48 Assessment by Combination Products, H2 2016 49 Number of Products by Stage and Target, H2 2016 51 Number of Products by Stage and Mechanism of Action, H2 2016 54 Number of Products by Stage and Route of Administration, H2 2016 58 Number of Products by Stage and Molecule Type, H2 2016 60 Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2016 196 Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2016 197
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.